NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide
Estimated value
—
Awarded value
£19.6m
Suppliers
11
Lots
1
Published
26 Mar 2026
Description
NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. Offer reference number: CM/PHG/24/5716 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Periods of call-offs under the framework agreement: CM/PHG/24/5716/01– NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide. CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028 NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028 LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
Scope
- Reference
- CM/PHG/24/5716
- Commercial tool
- Standalone contract
- Contract dates
- 31 May 2026 to 31 May 2028Possible extension to 31 May 2030
option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.
- CPV classifications
- 33600000
- Contract locations
- North East England, United KingdomNorth West England, United KingdomYorkshire and the Humber, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomEast of England, United KingdomLondon, United KingdomSouth East England, United KingdomSouth West England, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price | Price is not the only award criterion and all criteria are stated in the procurement documentation | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£19.6m
Award date
24 Mar 2026
Contract start
31 May 2026
Contract end
31 May 2028